<DOC>
	<DOCNO>NCT01437098</DOCNO>
	<brief_summary>The primary objective present trial demonstrate effectiveness safety MDT-2111 treatment symptomatic severe aortic stenosis subject deem difficult surgical operation .</brief_summary>
	<brief_title>Clinical Evaluation MDT-2111 Subjects With Symptomatic Severe Aortic Stenosis</brief_title>
	<detailed_description>Non-randomized , prospective , multicenter , single-arm trial .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . Subject must comorbidities one cardiologist one cardiac surgeon agree medical factor preclude operation , base conclusion probability death serious morbidity exceed probability meaningful improvement . 2 . Subject senile degenerative aortic valve stenosis : mean gradient &gt; 40 mmHg jet velocity great 4.0 m/s either rest dobutamine stress echocardiogram , simultaneous pressure recording cardiac catheterization ( either rest dobutamine stress ) , AND initial aortic valve area ≤ 0.8 cm² ( aortic valve area index ≤ 0.5 cm²/m² ) rest echocardiogram . 3 . Subject symptomatic his/her aortic valve stenosis , demonstrate NYHA Functional Class Class III great . If screening committee agree eligibility patient class II , base medical factor , he/she enrol . 4 . Subject informed nature trial sign Informed Consent Form . 5 . Subject agree comply specify followup evaluation return investigational site procedure perform . 1 . Evidence acute myocardial infarction ≤ 30 day prior intend treatment . 2 . Any percutaneous coronary peripheral interventional procedure perform within 30 day prior procedure . 3 . Blood dyscrasia define : Leukopenia ( WBC count &lt; 1,000 cells/mm³ ) Thrombocytopenia ( platelet count &lt; 50,000 cells/mm³ ) History bleed diathesis coagulopathy Hypercoagulable state 4 . Untreated clinically significant coronary artery disease require revascularization . 5 . Cardiogenic shock manifest low cardiac output , vasopressor dependence , mechanical hemodynamic support . 6 . Need emergency surgery reason . 7 . Severe ventricular dysfunction leave ventricular ejection fraction ( LVEF ) &lt; 20 % measure rest echocardiogram . 8 . Recent ( within 6 month ) cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) . 9 . End stage renal disease require chronic dialysis . 10 . GI bleed within past 3 month . 11 . A known hypersensitivity contraindication follow adequately premedicated : Aspirin Ticlopidine Heparin Contrast medium Nitinol ( titanium nickel alloy ) 12 . Ongoing sepsis , include active endocarditis . 13 . Subject refuse blood transfusion . 14 . Life expectancy &lt; 12 month due associate noncardiac comorbid condition . 15 . Other medical , social , psychological condition opinion Investigator precludes subject appropriate consent . 16 . Severe dementia ( result either inability provide inform consent trial/procedure , prevents independent lifestyle outside chronic care facility , fundamentally complicate rehabilitation procedure compliance followup visit ) . 17 . Currently participate investigational drug another device trial . Note : Trials require extend followup product investigational , since become commercially available , consider investigational trial . 18 . Symptomatic carotid vertebral artery disease . 19 . Native aortic annulus size &lt; 20 mm &gt; 27 mm per screen diagnostic imaging . 20 . Preexisting prosthetic heart valve position . 21 . Mixed aortic valve disease ( aortic stenosis aortic regurgitation predominant aortic regurgitation ) . 22 . Mitral regurgitation ( moderate severe ) severe tricuspid regurgitation . 23 . Moderate severe mitral stenosis . 24 . Hypertrophic obstructive cardiomyopathy . 25 . Echocardiographic evidence intracardiac mass , thrombus vegetation . 26 . Severe basal septal hypertrophy outflow gradient . 27 . Ascending aorta diameter &gt; 43 mm ( case aortic annulus 2327 mm ) unless aortic annulus 2023 mm case ascend aorta diameter &gt; 40 mm . 28 . Congenital bicuspid unicuspid valve verify echocardiography . 29 . For patient native coronary artery dependent circulation : Sinus valsalva width &lt; 29 mm unless aortic annulus 2023 mm , case sinus valsalva width &lt; 27 mm , OR Height leave right coronary sinus valsalva ( tubular aorta ) &lt; 15mm . 30 . Femoral iliac artery first choice correspond one following : Angle aortic root ( angle aortic valve annulus plane horizontal plane/vertebra ) exceed 70° . Vessel diameter femoral iliac artery le 6 mm . Aorta severe calcification , excess tortuosity severe atherosclerosis . Transarterial access able accommodate 18Fr sheath . 31 . Subclavian artery second choice correspond one following : Angle aortic root ( angle aortic valve annulus plane horizontal plane/vertebra ) exceed 70° ( case leave subclavian artery ) 30° ( case right subclavian artery ) . Vessel diameter subclavian artery le 6 mm . Transarterial access able accommodate 18Fr sheath . 32 . Direct Aortic Artery third line choice access . Patients exclude Direct Aortic access : Access site le 6 cm aortic valve basal plane Access site calcification porcelain aorta Access site delivery trajectory contain RIMA patent RIMA graft</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Valvular Heart Disease</keyword>
	<keyword>Severe Aortic Stenosis</keyword>
	<keyword>Aortic Valve Replacement</keyword>
</DOC>